Marketing-authorisation holder · Canada
Glenmark Pharmaceuticals Canada Inc.
40 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · Canada
40 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 40
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ATOVAQUONE AND PROGUANIL HYDROCHLORIDE TABLETS250 mg + 100 mg · Tablet | Atovaquone, Proguanil | Canada | Marketed | 2017 |
| DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS USP3 mg + 0.02 mg · Tablet | Drospirenone, Ethinyl estradiol | Canada | Marketed | 2021 |
| DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS USP 213 mg + 0.03 mg · Tablet | Drospirenone, Ethinyl estradiol | Canada | Marketed | 2021 |
| DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS USP 283 mg + 0.03 mg · Tablet | Drospirenone, Ethinyl estradiol | Canada | Marketed | 2021 |
| GLN-APREMILAST30 mg + 10 mg + 20 mg · Tablet | Apremilast | Canada | Authorised | |
| GLN-APREMILAST30 mg · Tablet | Apremilast | Canada | Not marketed | 2022 |
| GLN-ATOVAQUONE750 mg / 5 ml · Suspension | Atovaquone | Canada | Marketed | 2022 |
| GLN-BILASTINE20 mg · Tablet | Bilastine | Canada | Marketed | 2024 |
| GLN-DAPAGLIFLOZIN10 mg · Tablet | Dapagliflozin | Canada | Marketed | 2023 |
| GLN-DAPAGLIFLOZIN5 mg · Tablet | Dapagliflozin | Canada | Marketed | 2023 |
| GLN-DIMETHYL FUMARATE240 mg · Capsule (Delayed-Release) | Dimethyl | Canada | Not marketed | 2021 |
| GLN-DIMETHYL FUMARATE120 mg · Capsule (Delayed-Release) | Dimethyl | Canada | Not marketed | 2021 |
| GLN-EDOXABAN60 mg · Tablet | Edoxaban | Canada | Authorised | |
| GLN-EDOXABAN30 mg · Tablet | Edoxaban | Canada | Authorised | |
| GLN-EDOXABAN15 mg · Tablet | Edoxaban | Canada | Authorised | |
| GLN-EZETIMIBE10 mg · Tablet | Ezetimibe | Canada | Not marketed | 2019 |
| GLN-GABAPENTIN800 mg · Tablet | Gabapentin | Canada | Marketed | 2016 |
| GLN-GABAPENTIN600 mg · Tablet | Gabapentin | Canada | Marketed | 2016 |
| GLN-NINTEDANIB100 mg · Capsule | Nintedanib | Canada | Authorised | |
| GLN-NINTEDANIB150 mg · Capsule | Nintedanib | Canada | Authorised | |
| GLN-OLMESARTAN40 mg · Tablet | Olmesartan medoxomilo | Canada | Marketed | 2019 |
| GLN-OLMESARTAN20 mg · Tablet | Olmesartan medoxomilo | Canada | Marketed | 2019 |
| GLN-OLMESARTAN HCTZ12.5 mg + 20 mg · Tablet | Hydrochlorothiazide, Olmesartan medoxomilo | Canada | Marketed | 2020 |
| GLN-OLMESARTAN HCTZ12.5 mg + 40 mg · Tablet | Hydrochlorothiazide, Olmesartan medoxomilo | Canada | Marketed | 2020 |
| GLN-OLMESARTAN HCTZ25 mg + 40 mg · Tablet | Hydrochlorothiazide, Olmesartan medoxomilo | Canada | Marketed | 2020 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 40 | 37 | 3 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.